Subscribe to the newsletter


Signature of an exclusive licensing agreement and a new research collaboration in oncology with Ipsen

Published on March 8, 2023

The Institute for Research in Immunology and Cancer of the Université de Montréal (IRIC) is proud to announce that Ipsen has exercised its option to acquire exclusive rights to one of IRIC’s pre-clinical oncology programs, which was the result of a successful research collaboration between Ipsen, IRICoR and the Université de Montréal, initiated in May 2020. Ipsen will now lead all further activities for the worldwide development and commercialization of the resulting drug candidate.

In addition, Ipsen, IRICoR and the Université de Montréal are announcing the extension of their strategic research partnership with a new collaboration agreement and an option to license for two (2) new IRIC oncology research programs. Under this new agreement, teams at IRIC with specialized skills in both fundamental research and in drug discovery will work to identify, synthesize and develop high quality therapeutic agents, leading to the delivery of drug candidates.

“The discovery of a drug candidate exclusively licensed to Ipsen is another tangible example of the success of the research model established at IRIC, which has enabled the translation of the results of fundamental research into the discovery of new drug therapies. This level of success has been made possible thanks to the support of fundamental research and the Drug Discovery Unit of IRIC through funding from public agencies, philanthropic donations and investments by IRICoR and Ipsen. At IRIC, we believe that this type of significant collaboration involving a variety of stakeholders will allow us to reach our common objective: to provide promising new treatments to cancer patients”, said Michel Bouvier, Director-General of IRIC, at the Université de Montréal.

For further information: